Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bulevirtide - MYR Pharma

Drug Profile

Bulevirtide - MYR Pharma

Alternative Names: HEPCLUDEX; MyrB; Myrcludex-B; Myrcludex-B-MYR Pharma

Latest Information Update: 21 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator INSERM; University of Heidelberg
  • Developer Hepatera; MYR Pharma
  • Class Antihyperlipidaemics; Antivirals; Hepatoprotectants; Lipopeptides
  • Mechanism of Action Sodium-bile acid cotransporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis D
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hepatitis D
  • Phase II Hepatitis B
  • Preclinical Dyslipidaemias; Non-alcoholic steatohepatitis; Primary biliary cirrhosis

Most Recent Events

  • 17 Sep 2020 Launched for Hepatitis D in Germany, France, Austria (SC)
  • 04 Aug 2020 Registered for Hepatitis D in European Union (SC)
  • 02 Jun 2020 Bulevirtide - MYR Pharma is available for licensing in (excluding Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Uzbekistan) as of 02 Jun 2020. http://myr-pharma.com/ (MYR Pharma website, June 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top